EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced today it has signed an exclusive distribution agreement
The healthcare sector is experiencing a remarkable transformation driven by advancements in technology and an increasing focus on personalised medicine. Among the significant trends shaping the industry are the integration
EDX Medical Group plc (AQSE:EDX) CEO Dr Mike Hudson joins DirectorsTalk Interviews to discuss a strategic expansion of its cancer testing capability. In this interview with Dr Mike Hudson, CEO of
Cambridge-based EDX Medical is set to introduce a diagnostic tool in the UK aimed at identifying patients’ risk of developing hereditary cancer. This tool, which remains unnamed, focuses on germline
EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced a strategic expansion of its cancer
Nucleic acid-based biomarkers are integral to precision medicine, acting as indicators for a range of biological states, from disease predisposition to therapeutic effectiveness. Their application in numerous diseases necessitates thorough
EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making, enable
https://www.youtube.com/watch?v=EIoBQl90Xcg EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making,
Guardant Health, Inc. (NASDAQ: GH), a precision oncology company, has received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR 2017/746) for its Guardant360® CDx blood test. This certification,
The Guardant360 CDx blood test has received certification from TÜV SÜD Product Service under the European Union’s In Vitro Diagnostic Regulation (IVDR 2017/746) for tumour mutation profiling in patients with
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
